Rhes and RasGRP1 facilitate the development of L-DOPA-induced dyskinesia (LID) through the involvement of mammalian target of rapamycin (mTOR) signaling in a pre-clinical model of Parkinson's disease (PD) [9, 10]. The gene discussed is RASD2; the disease is Parkinson disease.